MedTrace Logo

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma

NCT00186238 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2010-09-14

No results posted yet for this study

Summary

To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.

Conditions

Interventions

PROCEDURE

high dose chemotherapy then autologous hematopoietic cell transplant

Sponsors & Collaborators

Principal Investigators

  • Sally Arai · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-09-30
Primary Completion
2006-09-30
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00186238 on ClinicalTrials.gov